News articles about Incyte (NASDAQ:INCY) have trended somewhat positive on Thursday, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Incyte earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.6757432244934 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
- New report examines the bromodomain containing protein 2 – pipeline review, trends & SWOT analysis H1 2017 (whatech.com)
- Castleman Disease Treatment Market Trends Estimates High Demand By 2017 – 2025 (newsmaker.com.au)
- Calithera Biosciences’ (CALA) CEO Susan Molineaux on Q2 2017 Results – Earnings Call Transcript (msn.com)
- Incyte Corporation (NASDAQ:INCY) Experiences Lighter than Average Trading Volume – Modern Readers (modernreaders.com)
- Insider Trading Activity Incyte Corporation (NASDAQ:INCY) – Insider Sold 3,000 shares of Stock (4-traders.com)
Several equities research analysts recently weighed in on the company. TheStreet upgraded Incyte from a “d+” rating to a “c” rating in a research report on Wednesday, May 24th. Cowen and Company restated a “buy” rating on shares of Incyte in a research report on Monday, June 5th. Credit Suisse Group restated a “buy” rating on shares of Incyte in a research report on Saturday, June 10th. Zacks Investment Research upgraded Incyte from a “sell” rating to a “hold” rating in a research report on Tuesday, April 18th. Finally, Raymond James Financial, Inc. restated a “hold” rating on shares of Incyte in a research report on Monday, April 17th. Seven equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $140.39.
Shares of Incyte (INCY) opened at 130.08 on Thursday. The stock’s market cap is $26.76 billion. The company’s 50-day moving average price is $130.84 and its 200-day moving average price is $128.99. Incyte has a 52-week low of $75.52 and a 52-week high of $153.15.
Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $326.40 million during the quarter, compared to analyst estimates of $318.45 million. Incyte had a negative return on equity of 5.03% and a negative net margin of 3.82%. The firm’s revenue for the quarter was up 32.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.18 EPS. On average, equities research analysts forecast that Incyte will post ($0.89) earnings per share for the current fiscal year.
In other Incyte news, EVP Eric H. Siegel sold 1,820 shares of Incyte stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $132.92, for a total transaction of $241,914.40. Following the completion of the sale, the executive vice president now owns 23,553 shares of the company’s stock, valued at approximately $3,130,664.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO David W. Gryska sold 16,756 shares of Incyte stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $116.60, for a total value of $1,953,749.60. Following the sale, the chief financial officer now directly owns 35,771 shares of the company’s stock, valued at approximately $4,170,898.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,183 shares of company stock valued at $5,976,946. 17.70% of the stock is currently owned by insiders.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related companies with MarketBeat.com's FREE daily email newsletter.